Yale Study Puts Intradermal Influenza Vaccination Under an Immune Microscope
A Yale-led early-phase study is using seasonal influenza vaccination as a controlled immune challenge to compare what happens in the skin and in the bloodstream after an intradermal shot. The trial pairs an FDA-approved seasonal flu vaccine with the MicronJet microneedle device and follows immune responses across serial time points after vaccination. Investigators are not simply asking whether antibodies rise. They are trying to determine which baseline features in skin and peripheral blood predict the magnitude, timing, and durability of the response.
The study is open-label, prospective, single-site, and exploratory. It is also deliberately broad in the biology it intends to capture: antibody titers, cell subtypes, and multi-omic profiles from both local tissue and blood. A seasonal influenza vaccine becomes a probe for host immunity, allowing investigators to interrogate the innate and adaptive arms of the immune system in real time. Because the skin is densely populated with antigen-presenting cells and resident immune populations, intradermal delivery may expose response patterns that are less visible after standard intramuscular injection.
One sentence captures the central wager: the skin may reveal immune behavior the blood alone cannot.
Skin-Based Sampling May Reveal Earlier Immune Signatures
The protocol is built around the idea that early post-vaccination biology can explain later vaccine performance. Participants provide samples before vaccination and then again after vaccination at several time points. The primary immunogenicity measure is the change in influenza microneutralization antibody titers from Day 0 to Day 28. That endpoint focuses on functional antibody activity rather than a purely descriptive serologic readout, which makes it more useful for linking immune activation to likely protection.
Intradermal administration uses a 0.3 mL dose delivered with the MicronJet600 device. The vaccine itself is a season-appropriate Fluzone formulation, approved for intramuscular use, while the intradermal route is off-label and conducted under an investigational exemption tied to an IND process. Participants assigned to intramuscular vaccination receive the dose specified for their cohort and influenza season. Optional stool sampling adds a microbiome-adjacent dimension to the study, although the main readouts remain skin, blood, and antibody kinetics.
The design gives investigators room to ask where the immune system first organizes its response. Local inflammation in the skin, shifts in cell subsets, and molecular signatures may all precede or help explain the eventual antibody rise. In a vaccination study, those details matter because they can distinguish a simple peak from a coordinated immune program.
Healthy Adults, Cancer Patients, and PAIS Participants Will Be Compared
The study includes three participant groups: healthy adults, adults with cancer preparing to begin immune checkpoint inhibitor therapy, and adults with physician-diagnosed post-acute infection syndrome, including long COVID and long Lyme disease or post-treatment Lyme disease syndrome. Enrollment is estimated at 139 participants, and the study is scheduled to run through May 2029. The study began on October 1, 2026.
Healthy participants must be 18 to 40 years old at enrollment, speak, read, and write English proficiently, and be in good general health. Cancer participants must be cleared for influenza vaccination by their oncology team, which must also judge that study participation will not interfere with care or other trials. PAIS participants must be eligible for influenza vaccination by their referring provider and must have documentation of infection, including COVID-19 or Lyme disease.
Those eligibility rules are more than administrative detail. They create biologically distinct cohorts that may respond differently to the same vaccine stimulus. Cancer patients approaching immune checkpoint inhibitor therapy may already sit at a different immunologic baseline from healthy volunteers, while PAIS participants may have lingering immune dysregulation after infection. Comparing those groups could expose whether intradermal vaccination amplifies, normalizes, or merely mirrors preexisting immune variation.
Immune Exclusions Are Built to Reduce Noise in the Readouts
The exclusion criteria are extensive, and for good reason. Recent vaccinations, active infections, glucocorticoid exposure, immunoglobulin therapy, recent blood products, autoimmune disease, bleeding disorders, keloids, and pregnancy all appear among the exclusions for the healthy arm. The protocol also excludes participants with known or suspected immunodeficiency, documented HIV infection, a body mass index of 30 or higher, or a history of Guillain-Barre syndrome.
Those restrictions are aimed at protecting participants, but they also protect the interpretability of the biology. Immune profiling studies can be derailed by even modest background inflammation, recent antigen exposure, or therapies that alter lymphocyte trafficking and cytokine signaling. By tightening the screen, investigators increase the odds that the changes observed after vaccination reflect the vaccine challenge itself rather than unrelated immune perturbations.
A second sentence lands with equal force: this is a controlled perturbation study, not a routine flu-shot clinic.
Microneutralization Titers Anchor the Trial Around Functional Immunity
The choice of influenza microneutralization titers as the primary measure points to a clinically meaningful question: does intradermal delivery shape the functional quality of the response? Antibody quantity alone can miss differences in neutralizing capacity, and cell-based profiles can be hard to interpret without a companion serologic anchor. By linking local skin events to a Day 28 neutralization change, the study can connect upstream immune activation to downstream effector function.
The broader scientific value comes from the timing. Early innate signaling in the skin often sets the tone for antigen presentation, T-cell priming, and later B-cell maturation. If baseline skin features or early post-vaccination signatures predict stronger or more durable neutralization, the findings could help explain why some hosts respond well to vaccination while others do not. That could matter in populations with altered immune states, especially patients preparing for cancer immunotherapy or living with post-infectious syndromes.
The study also has a translational edge because it uses an already licensed seasonal influenza vaccine. Rather than inventing a new antigen, investigators are examining how route of administration and host biology interact under a familiar real-world immunization platform. That makes the protocol conceptually elegant and clinically recognizable.
What This Trial Can and Cannot Answer Yet
The study is still early phase 1, open-label, and exploratory, so it is built to generate immune maps rather than definitive practice-changing comparisons. No results are posted yet. The cancer and PAIS arms are explicitly exploratory, which means their role is hypothesis-generating rather than confirmatory. The single-site design may also limit how broadly the findings can be generalized beyond the Yale setting.
Even so, the trial is structured to answer a practical immunology question that has been difficult to resolve in routine vaccination research: what does a vaccine response look like when the skin, blood, and baseline host state are measured together? If intradermal vaccination produces distinct local immune kinetics or reveals baseline correlates of response, future work could refine how intradermal routes are studied in immunocompromised or post-infectious populations. For now, the most concrete deliverable is a detailed account of how the skin behaves when an FDA-approved influenza vaccine is delivered through a microneedle device rather than a conventional intramuscular injection.
The trial’s real test is whether those skin-level signals align with functional neutralization by Day 28, and whether that alignment differs across healthy adults, cancer patients, and PAIS participants.